Dossier assessment

Apalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V

Report documents

Indication:

Patients with metastatic hormone-sensitive prostate cancer

Result of dossier assessment:

For patients in good general condition: hint of non-quantifiable added benefit

Federal Joint Committee (G-BA)

2020-08-20: G-BA decision was published.

Project no.: A20-20
Commission: Commission awarded on 25.02.2020 by the Federal Joint Committee (GBA).
Report type: Dossier assessment
Status: Commission completed
Department/Division: Drug Assessment
Topic: Cancer
Note: After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.